Argyll Biotechnologies

Argyll Biotechnologies is a biotechnology company primarily focused on the development of novel oncology therapeutics targeting the insulin-like growth factor 1 receptor (IGF-1R). The company's lead product candidate, AXL-1717 (picropodophyllin), is a first-in-class, orally active small molecule inhibitor designed to selectively block IGF-1R without affecting the closely related insulin receptor. Clinical development has focused on indications such as non-small cell lung cancer (NSCLC) and various solid tumors, including brain cancers like glioblastoma. Argyll's technology originated from research conducted at the Karolinska Institute in Sweden. While the company reached mid-stage clinical trials, its recent operational status is characterized by limited public activity. The therapeutic approach aims to provide a more targeted and less toxic alternative to traditional chemotherapy by disrupting essential survival signals in cancer cells.